Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HMPL-306 in relapsed or refractory IDH1- and/or IDH2-mutated acute myeloid leukemia: A phase 1 study.

Med (New York, N.Y.) - 13 Jun 2025

Hu Lijuan, Wei Xudong, Zhao Weili, Hu Yu, Li Juan, Dong Yugang, Gong Tiejun, Zhang Xuhan, Xu Yajing, Zhang Yu, Xu Chongyuan, Zhang Cheng, Cai Zhen, Jing Hongmei, Mi Ruihua, Wu Wen, He Wenjuan, Wang Hehua, Tang Qinghua, Jiang Zhiping, Liu Hui, Chen Guo, Sun Jie, Chen Jian, Yan Sai, Yan Huan, Wangwu Jiaxuan, Zhong Zeyu, Wang Linfang, Fan Songhua, Shi Michael, Su Weiguo, Huang Xiaojun

Abstract excerpt

BACKGROUND: HMPL-306 has equally high inhibitory activity against mutated isocitrate dehydrogenases 1 and 2 (mIDH1/2). METHODS: This first-in-human, phase 1 dose-escalation/dose-expansion study (this study was registered at ClinicalTrials.gov: NCT04272957) enrolled patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) harboring mIDH1 and/or mIDH2. Patients received 25-250 mg of HMPL-306 orally once...

Topics

Join the communities discussing this publication.

Aged
Aged, 80 and over
Antineoplastic Agents
Dose-Response Relationship, Drug

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Isocitrate Dehydrogenase

Leukemia, Myeloid, Acute

Maximum Tolerated Dose

Source

Identifiers

PMID: 39892383
DOI: 10.1016/j.medj.2025.100575

Genes

IDH1
IDH2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HMPL-306 in relapsed or refractory IDH1- and/or IDH2-mutated acute myeloid leukemia: A phase 1 study.PMID 39892383Read ↗

More than just another IDH inhibitor: Insights from the HMPL-306 phase 1 trial.Semantic proximity Read ↗

Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AMLSemantic proximity Read ↗

Olutasidenib for mutated IDH1 acute myeloid leukemia: final five-year results from the phase 2 pivotal cohort.Semantic proximity Read ↗

Olutasidenib: a novel mutant IDH1 inhibitor for the treatment of relapsed or refractory acute myeloid leukemia.Semantic proximity Read ↗

Resistance to mutant IDH inhibitors in acute myeloid leukemia: Molecular mechanisms and therapeutic strategies.Semantic proximity Read ↗

Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia.Semantic proximity Read ↗

HMPL-306 (Ranosidenib): The Next Frontier in mIDH Cancer TherapySemantic proximity Read ↗

Isocitrate Dehydrogenase Inhibitors in Acute Myeloid Leukemia.Semantic proximity Read ↗

Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia.Semantic proximity Read ↗

Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome.Semantic proximity Read ↗

Efficacy and safety of FDA-approved IDH inhibitors in the treatment of IDH mutated acute myeloid leukemia: a systematic review and meta-analysis.Semantic proximity Read ↗

Clinical Implications of Isocitrate Dehydrogenase Mutations and Targeted Treatment of Acute Myeloid Leukemia with Mutant Isocitrate Dehydrogenase Inhibitors-Recent Advances, Challenges and Future Prospects.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.